The application of selective nonsteroidal anti-inflammatory medications under implementation of rehabilitation measures to patients with osteoarthritis

Abstract

The results of comparative analysis of two medications demonstrate high safety and good toleration during treatment with new selective NSAID Arthrosan in patients with osteoarthritis. The arthrosan farmacodynamic effects and safety concerning gastro adverse events are comparable with diclofenac therapy combined with proton pump inhibitor. The study results demonstrate that during treatment of osteoarthritis in patients without gastrointestinal tract pathology both diclofenac and arthrosan can be applied. In the case of gastrointestinal pathology the only choice is Arthrosan.

Keywords

osteoarthritis / nonsteroidal anti-inflammatory medicines

References

[1] Зоткин Е.Г. Рациональная терапия остеоаргроза // Науч.- практ. ревматол. - 2005. - № 5. - С. 48-51.

[2] Игнатов Ю.Д., Кукес В.Г., Мазуров В.И. Клиническая фармакология нестероидных противовоспалительных средств. - М., 2010.

[3] Применение нестероидных противовоспалительных препаратов / Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. - М., 2009.

[4] Насонова В.А., Алексеева Л.И., Насонов Е.Л. Остеоартроз тазобедренного сустава: течение, лечение и профилактика // Consilium Medicum. - 2002. - Т. 5. № 8. - С. 434-438.

[5] Насонов Е.Л. Специфические ингибиторы циклооксигеназы 2 и воспаления: перспективы применения препарата целебрекс // Рос. ревматол. - 1999. - № 4. - С. 2-13.

[6] Насонов Е.Л. Современные направления фармакотерапии остеоартроза // Consilium Medicum. - 2001. - Т. 3., № 9. - С. 408-412.

[7] Фоломеева О.М., Эрдес Ш. Социальные аспекты ревматических заболеваний в России // Современные методы диагностики и лечения ревматических заболеваний. - М., 2006. - С. 14-20.

[8] Brooks Р.М., Day R.О. Nonsteroidal antiinfla mmatory drugs - differences and similarities // N. Engl. J. Med. - 1991. - Vol. 324. - P. 1716-1725.

[9] Champion G.D., Feng P.H., Azuma T. et al. NSAlD-induced gastrointestinal damage // Drugs. - 1997. - Vol. 53. - P. 6- 19.

[10] Espinosa L., Lipani J., Poland М., Wallin B. Perforations, ulcers and bleeds in a large, randomized, multicenter trial of namubetone compared with diclofenac, ibuprofen, naproxen and piroxicam // Rev. Esp. Reumatol. - 1993. - Vol. 20, Suppl. I). - P. 324.

[11] Gillis J.C., Brogden R.N. Ketorolak. A reappraisal of its pharmacodinamic and pharmacokinetic properties and therapeutic use in pain management // Drugs, - 1997, - Vol. 53, - P. 139-188.

[12] Guslandi M. Gastric toxicity of anti platelet therapy with low-dose aspirin // Drugs. - 1997. - Vol. 53. - P. 1-5.

[13] Insel P.A. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout // Goodman & Gilman’s The Pharmacological Basis of Therapeutics. - 9th Ed. - New York, 1996. - P. 617-657.

[14] Konstan M.W., Byard P.J., Hoppel C.L., Davis P.B. Effect of high dose ibuprofen in patients with cystic fibrosis // N. Engl. J. - Med. - 1995. - Vol. 332. - P. 848-854.

[15] Laurence D.R., Bennett P.N. Clinical Pharmacology. - 7th Ed. - Edinburgh, 1992.

[16] Loeb D.S., Ahlquist D.A., Talley N.J. Management of gastroduo-denopathy associated with use of nonsteroidal anti-inflammatory drugs j j Mayo Clin. Proc. - 1992. - Vol. 67. - P. 354-364.

[17] Noble S., Balfour J. Meloxicam // Drugs. - 1996. - Vol. 51. - P. 424-430.

[18] Perneger Т.V., Whelton P.K., Klag M.J. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs // N. Engl. J. Med. - 1994. - Vol. 331. - P. 1675-1712.

RIGHTS & PERMISSIONS

Eco-Vector